Kaveri Pohlman
Stock Analyst at Clear Street
(3.17)
# 2,433
Out of 4,382 analysts
229
Total ratings
34.8%
Success rate
3.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LBRX LB Pharmaceuticals | Initiated Coverage: Buy | $45 | $28.60 | +57.34% | 1 | May 26, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $33 | $13.51 | +144.26% | 18 | May 19, 2026 | |
| SGMT Sagimet Biosciences | Maintained: Buy | $37 → $28 | $6.76 | +314.20% | 4 | May 13, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | $70 | $17.90 | +291.06% | 5 | May 10, 2026 | |
| TRVI Trevi Therapeutics | Maintained: Buy | $21 → $29 | $13.33 | +117.55% | 3 | May 7, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $533 → $680 | $486.98 | +39.64% | 3 | May 6, 2026 | |
| ORKA Oruka Therapeutics | Maintained: Buy | $71 → $131 | $60.14 | +117.83% | 4 | Apr 27, 2026 | |
| ELVN Enliven Therapeutics | Maintained: Buy | $36 → $55 | $34.71 | +58.46% | 2 | Apr 27, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Buy | $104 → $116 | $97.38 | +19.12% | 5 | Apr 6, 2026 | |
| PALI Palisade Bio | Maintained: Buy | $12 | $1.74 | +589.66% | 2 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $53 | $19.92 | +166.06% | 1 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $11 → $20 | $11.97 | +67.08% | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 → $220 | $108.67 | +102.45% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $12 | $13.35 | -10.11% | 4 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $9.79 | +83.86% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 → $99 | $37.58 | +163.44% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $16.94 | +47.58% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $3.40 | +429.41% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $4.82 | +148.96% | 17 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 → $47 | $30.35 | +54.86% | 2 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $52.70 | n/a | 8 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.92 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.77 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $23.19 | n/a | 30 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $25.15 | n/a | 18 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $9.47 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.58 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.78 | n/a | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $3.33 | n/a | 17 | Jun 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $1.26 | n/a | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | n/a | 6 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $8 | $3.00 | n/a | 3 | Jul 6, 2022 |
LB Pharmaceuticals
May 26, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $28.60
Upside: +57.34%
Cullinan Therapeutics
May 19, 2026
Maintained: Buy
Price Target: $33
Current: $13.51
Upside: +144.26%
Sagimet Biosciences
May 13, 2026
Maintained: Buy
Price Target: $37 → $28
Current: $6.76
Upside: +314.20%
MoonLake Immunotherapeutics
May 10, 2026
Maintained: Buy
Price Target: $70
Current: $17.90
Upside: +291.06%
Trevi Therapeutics
May 7, 2026
Maintained: Buy
Price Target: $21 → $29
Current: $13.33
Upside: +117.55%
Madrigal Pharmaceuticals
May 6, 2026
Maintained: Buy
Price Target: $533 → $680
Current: $486.98
Upside: +39.64%
Oruka Therapeutics
Apr 27, 2026
Maintained: Buy
Price Target: $71 → $131
Current: $60.14
Upside: +117.83%
Enliven Therapeutics
Apr 27, 2026
Maintained: Buy
Price Target: $36 → $55
Current: $34.71
Upside: +58.46%
Protagonist Therapeutics
Apr 6, 2026
Maintained: Buy
Price Target: $104 → $116
Current: $97.38
Upside: +19.12%
Palisade Bio
Mar 31, 2026
Maintained: Buy
Price Target: $12
Current: $1.74
Upside: +589.66%
Mar 17, 2026
Initiated Coverage: Buy
Price Target: $53
Current: $19.92
Upside: +166.06%
Mar 6, 2026
Rated: Buy
Price Target: $11 → $20
Current: $11.97
Upside: +67.08%
Mar 2, 2026
Maintained: Buy
Price Target: $200 → $220
Current: $108.67
Upside: +102.45%
Jan 20, 2026
Downgraded: Hold
Price Target: $32 → $12
Current: $13.35
Upside: -10.11%
Dec 11, 2025
Reiterated: Buy
Price Target: $18
Current: $9.79
Upside: +83.86%
Dec 9, 2025
Maintained: Buy
Price Target: $61 → $99
Current: $37.58
Upside: +163.44%
Dec 1, 2025
Maintained: Buy
Price Target: $25
Current: $16.94
Upside: +47.58%
Dec 1, 2025
Maintained: Buy
Price Target: $18
Current: $3.40
Upside: +429.41%
Nov 26, 2025
Maintained: Buy
Price Target: $12
Current: $4.82
Upside: +148.96%
Nov 11, 2025
Maintained: Buy
Price Target: $32 → $47
Current: $30.35
Upside: +54.86%
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $52.70
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $3.92
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $11.77
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $23.19
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $25.15
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $9.47
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $4.58
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $1.78
Upside: n/a
Jun 2, 2024
Maintained: Buy
Price Target: $13
Current: $3.33
Upside: n/a
Apr 29, 2024
Maintained: Buy
Price Target: $21
Current: $1.26
Upside: n/a
Nov 23, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Jul 6, 2022
Rated: Buy
Price Target: $16 → $8
Current: $3.00
Upside: n/a